A randomized controlled pilot of Laurus nobilis Tea on inflammatory biomarkers

The effect of daily Laurus nobilis tea on inflammatory biomarkers: A randomized controlled pilot study in Healthy North-African Volunteers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202205585377035

Enrollment

Registered

2022-05-13

Start date

2022-05-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine Cardiology

Interventions

Origanum syriacum L

Laurus nobilis tea

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: No smoking No vegetarian diet No pregnancy No consumption of medication or nutritional supplements No any anti-inflammatory treatment (non-steroid anti-inflammatory drug, corticosteroid or other anti-inflammatory drug) No chronic pathologies (eg; cardiovascular diseases, diabetes-mellitus, arterial-hypertension, asthma, psychiatric disorders, gastrointestinal problems) No food allergy

Exclusion criteria

Exclusion criteria: The absence during the second visit (ie; Day11 of the study) The non-consumption of the Lnt or the placebo tea at least one time

Design outcomes

Primary

Measure	Time frame
Neutrophil/lymphocyte ratio (NLR)	—

Secondary

Measure	Time frame
White blood cell count (WBC), neutrophil count, lymphocyte count, platelet and monocyte count analysis	—

Countries

Tunisia

Contacts

Public ContactChahra Chbili

Metabolic Biophysics and Applied Pharmacology Laboratory Faculty of Medicine Sousse Tunisia

chahrachbili@yahoo.fr+21693645001

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026